Saltar al contenido
Merck

SML3976

Sigma-Aldrich

Apremilast

≥98% (HPLC)

Sinónimos:

(S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulphonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide, CC 10004, CC-10004, CC10004, N-[2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C22H24N2O7S
Número de CAS:
Peso molecular:
460.50
MDL number:
UNSPSC Code:
12352200

Quality Level

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Biochem/physiol Actions

Orally active, potent and selective phosphodiesterase 4 (PDE4) inhibitor in vitro and in vivo.



Apremilast (CC-10004) is an orally active, potent and selective phosphodiesterase 4 (PDE4) inhibitor (IC50 = 20/49/50/30 nM with recombinant human PDE4A4/B2/C2/D3 and 1 μM cAMP; no significant PDE1/2/3/5/7/8/9/10/11 inhibition at 10 μM). Apremilast effectively inhibits LPS-induced cytokine and chemokine protein expression from purified human PBMCs (TNFα/IFNγ/IL12 IC50 = 13/110/120 nM, IP10/MIG/MIP1α IC50 = 10/28/40 nM) in vitro and exhibits therapeutic efficacy in a psoriasis mouse model in vivo (2.5/mg/kg b.i.d. p.o.)

pictograms

Health hazardExclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Lact. - Repr. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Fiona E McCann et al.
Arthritis research & therapy, 12(3), R107-R107 (2010-06-08)
Type 4 phosphodiesterases (PDE4) play an important role in immune cells through the hydrolysis of the second messenger, cAMP. Inhibition of PDE4 has previously been shown to suppress immune and inflammatory responses, demonstrating PDE4 to be a valid therapeutic target
P H Schafer et al.
British journal of pharmacology, 159(4), 842-855 (2010-01-07)
Apremilast is an orally administered phosphodiesterase-4 inhibitor, currently in phase 2 clinical studies of psoriasis and other chronic inflammatory diseases. The inhibitory effects of apremilast on pro-inflammatory responses of human primary peripheral blood mononuclear cells (PBMC), polymorphonuclear cells, natural killer
Hon-Wah Man et al.
Journal of medicinal chemistry, 52(6), 1522-1524 (2009-03-05)
In this communication, we report the discovery of 1S (apremilast), a novel potent and orally active phosphodiesterase 4 (PDE4) and tumor necrosis factor-alpha inhibitor. The optimization of previously reported 3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-3-(3,4-dimethoxyphenyl)propionic acid PDE4 inhibitors led to this series of sulfone analogues.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico